Efforts to improve the oral bioavailability of cyclosporine A (CyA) remains a challenge in the
field of drug delivery. In this study, glyceryl monooleate (GMO)/poloxamer 407 cubic …

Cyclosporine (CyA) was incorporated into polycaprolactone nanoparticles (PCL-NP) in
order to increase its oral bioavailability and to control drug distribution, thereby potentially …

The purpose of this work was to improve the oral bioavailability of cyclosporine A (CyA) by
preparation the CyA-pH sensitive nanoparticles. The CyA-pH sensitive nanoparticles were …

The hydrophobic cyclic undecapeptide cyclosporin A (CyA) used in the prevention of graft
rejection and in the treatment of autoimmune diseases was encapsulated by …

A wide range of nanoparticles has been explored for the delivery of highly hydrophobic
drugs, but very few publications provide comparative data of the performance of different …

Cyclosporine A-nanosuspensions were prepared using zirconium oxide beads as a milling
media, Poloxamer 407 as a stabilizer and distilled water as an aqueous medium using the …

The cyclic undecapeptide cyclosporin A (CYA) used as first-line therapy in the prevention of
xenograft rejection following organ transplantation, is extremely hydrophobic. Marketed …

The pH-sensitive cyclosporine A (CyA) nanoparticles were prepared by the solvent
displacement method with enteric dissolved polymer of hydroxypropyl methylcellulose …

In this study, cyclosporin-A (Cy-A) a highly lipophilic, poorly absorbable drug can be
prepared easily and reproducibly as positively and negatively charged nanoparticles with …

For the development of an optimized oral formulation for cyclosporine A, 2% of this drug has
been formulated in solid lipid nanoparticles (SLN™, mean size 157nm) and as nanocrystals …